Diagenode

Micro-ribonucleic acid-155 is a direct target of Meis1, but not a driver in acute myeloid leukemia


Schneider E. et al.

Micro-ribonucleic acid-155 (miR-155) is one of the first described oncogenic miRNAs. Although multiple direct targets of miR-155 have been identified, it is not clear how it contributes to the pathogenesis of acute myeloid leukemia. We found miR-155 to be a direct target of Meis1 in murine Hoxa9/Meis1 induced acute myeloid leukemia. The additional overexpression of miR-155 accelerated the formation of acute myeloid leukemia in Hoxa9 as well as in Hoxa9/Meis1 cells in vivo However, in the absence or following the removal of miR-155, leukemia onset and progression were unaffected. Although miR-155 accelerated growth and homing in addition to impairing differentiation, our data underscore the pathophysiological relevance of miR-155 as an accelerator rather than a driver of leukemogenesis. This further highlights the complexity of the oncogenic program of Meis1 to compensate for the loss of a potent oncogene such as miR-155. These findings are highly relevant to current and developing approaches for targeting miR-155 in acute myeloid leukemia.

Tags
Antibody

Share this article

Published
February, 2018

Source

Products used in this publication

  • Antibody ChIP-seq grade icon
    C15410194
    H3K4me1 polyclonal antibody - Premium
  • Antibody ChIP-seq grade icon
    C15410003-50
    H3K4me3 polyclonal antibody - Premium

Events

  • ASHG
    Houston, TX
    Oct 15-Oct 19, 2019
  • ddd
    dd
    Oct 18-Oct 26, 2019
  • Neuroscience 2019
    Chicago, IL
    Oct 19-Oct 23, 2019
 See all events

       Site map   |   Contact us   |   Conditions of sales   |   Conditions of purchase   |   Privacy policy   |   Diagenode Diagnostics